학술논문
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
Document Type
article
Author
Costanza Paoletti; Meredith M. Regan; Samuel M. Niman; Emily M. Dolce; Elizabeth P. Darga; Minetta C. Liu; P. Kelly Marcom; Lowell L. Hart; John W. Smith; Karen L. Tedesco; Eitan Amir; Ian E. Krop; Angela M. DeMichele; Pamela J. Goodwin; Margaret Block; Kimberly Aung; Martha E. Brown; Robert T. McCormack; Daniel F. Hayes
Source
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Subject
Language
English
ISSN
2374-4677
Abstract
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, might predict resistance to endocrine therapy (ET) in patients with ER-positive MBC. One hundred twenty-one patients with ER-positive/HER2-negative MBC initiating a new ET after ≥1 lines of ET were enrolled in a prospective, multi-institutional clinical trial. CTC-ETI and clinical/imaging follow-up were performed at baseline and serial time points. Progression-free survival (PFS) and rapid progression (RP; determined at the 3-month time point) were primary endpoints. Associations with clinical outcomes used logrank and Fisher’s exact tests. At baseline, 36% (38/107) of patients had ≥5 CTC/7.5 ml whole blood (WB). Patients with ≥5 vs.